Targeting the PD-1 pathway in pediatric solid tumors and brain tumors.

Content Provider	Europe PMC
Author	Wagner, Lars M Adams, Val R
Copyright Year	2017
Abstract	While remarkable advances have been made in the treatment of pediatric leukemia over the past decades, new therapies are needed for children with advanced solid tumors and high-grade brain tumors who fail standard chemotherapy regimens. Immunotherapy with immune checkpoint inhibitors acting through the programmed cell death-1 (PD-1) pathway has shown efficacy in some chemotherapy-resistant adult cancers, generating interest that these agents may also be helpful to treat certain refractory pediatric malignancies. In this manuscript we review current strategies for targeting the PD-1 pathway, highlighting putative biomarkers and the rationale for investigation of these drugs to treat common pediatric tumors such as sarcoma, neuroblastoma, and high-grade glioma. We summarize the completed and ongoing clinical trial data available, and suggest potential applications for further study.
Journal	Oncotargets and Therapy
Volume Number	10
PubMed Central reference number	PMC5396947
PubMed reference number	28442918
e-ISSN	11786930
DOI	10.2147/ott.s124008
Language	English
Publisher	Dove Medical Press
Publisher Date	2017-04-12
Access Restriction	Open
Rights License	The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. © 2017 Wagner and Adams. This work is published and licensed by Dove Medical Press Limited
Subject Keyword	PD-1 nivolumab pembrolizumab pediatric sarcoma neuroblastoma glioma
Content Type	Text
Resource Type	Article
Subject	Pharmacology (medical) Oncology